Edition:
United States

Mylan NV (MYL.OQ)

MYL.OQ on NASDAQ Stock Exchange Global Select Market

30.32USD
4:00pm EDT
Change (% chg)

$-0.41 (-1.33%)
Prev Close
$30.73
Open
$30.51
Day's High
$30.80
Day's Low
$30.17
Volume
1,162,540
Avg. Vol
2,003,837
52-wk High
$47.50
52-wk Low
$29.44

MYL.OQ

Chart for MYL.OQ

About

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, brand name and over-the-counter (OTC) products in a range of dosage forms and therapeutic categories. It operates through three segments on a geographic basis, North America, Europe and Rest of World. The... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $16,479.91
Shares Outstanding(Mil.): 536.28
Dividend: --
Yield (%): --

Financials

  MYL.OQ Industry Sector
P/E (TTM): 25.06 31.70 32.82
EPS (TTM): 1.23 -- --
ROI: 2.39 15.41 14.97
ROE: 5.71 16.43 16.21

Mylan, U.S. finalize $465 million EpiPen settlement

BOSTON Mylan NV has finalized a $465 million settlement resolving U.S. Justice Department claims it overcharged the government for its EpiPen emergency allergy treatment, which became the center of a firestorm over price increases.

Aug 17 2017

UPDATE 5-Mylan, U.S. finalize $465 million EpiPen settlement

BOSTON, Aug 17 Mylan NV has finalized a $465 million settlement resolving U.S. Justice Department claims it overcharged the government for its EpiPen emergency allergy treatment, which became the center of a firestorm over price increases.

Aug 17 2017

BRIEF-Mylan finalizes settlement on Medicaid rebate classification for Epipen

* Mylan finalizes settlement agreement on Medicaid rebate classification for Epipen auto-injector

Aug 17 2017

BRIEF-Mylan launches three generic antiretroviral medicines in Canada

* Mylan advances access in the fight against HIV with the launch of three generic antiretroviral medicines in Canada

Aug 10 2017

UPDATE 4-Mylan cuts forecasts on delays in new drugs, weak prices

Aug 9 Mylan NV said on Wednesday that delays in launching key new drugs and eroding prices for generics in the United States will hurt its profitability this year and in 2018.

Aug 09 2017

Mylan cuts forecasts on delays in new drugs, weak prices

Mylan NV said on Wednesday that delays in launching key new drugs and eroding prices for generics in the United States will hurt its profitability this year and in 2018. | Video

Aug 09 2017

BRIEF-Mylan gives details on genric approval processes

* Says disappointed with the execution by FDA on approval process of generic Copaxone

Aug 09 2017

BRIEF-Mylan reports Q2 GAAP earnings per share $0.55

* Mylan reports second quarter 2017 results and updates 2017 guidance

Aug 09 2017

Mylan profit jumps 76.4 percent

Aug 9 Generic drug maker Mylan NV reported a 76.4 percent increase in quarterly profit on Wednesday, helped by demand for products it gained through the acquisition of Swedish drugmaker Meda last year.

Aug 09 2017

UPDATE 3-CVS Health's dull Q3 forecast overshadows profit beat

* Shares down 1.4 pct (Adds investor comment, company response; updates shares)

Aug 08 2017

Earnings vs. Estimates